InDex To Fly Solo With Ulcerative Colitis Drug In US
Cobitolimod Touted As Blockbuster
Executive Summary
Approval is unlikely before 2027 but Sweden’s InDex has done the maths and decided that it can launch cobitolimod across the Atlantic on its own with a staff of around 100.
You may also be interested in...
Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
France's Abivax Looks A Likely M&A Target
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.